The Prevalence of Thyroid Autoimmunity in Pregnancy and Adverse Neonatal Outcomes at a Secondary Care Hospital in the Middle East

Abstract

Background and objective Among the common endocrinological disorders of pregnancy, thyroid disorders rank second after diabetes. Thyroid autoimmunity is linked to sub-fertility, miscarriages, preterm birth, gestational diabetes, and adverse neurodevelopmental sequelae in children. Peroxidase and thyroglobulin autoantibodies may be associated with enhanced global autoimmune state, which may have adverse effects on the fetal or placental development. It is the main cause of hypothyroidism in reproductive-age women and is associated with poor obstetric outcomes. In Gulf countries, a higher prevalence of thyroid antibodies during pregnancy was reported. However, there is paucity of data in the literature in the Gulf countries in this regard. Our study was conducted to assess the effects of thyroid antibodies on adverse maternal and neonatal outcomes in pregnancy in a multiethnic population of Qatar. The study aimed to assess the prevalence of thyroid antibodies in pregnant hypothyroid women and their impact on adverse fetal outcomes in pregnancy. Design A Retrospective study of patients' notes (retrospective chart review) was conducted at a secondary hospital in Qatar. Records of the women who delivered from January 2017 to June 2018 were evaluated. A total of 384 women were included after applying exclusion criteria. Neonatal outcomes were compared in hypothyroid women with (group A1) and without thyroid antibodies (group A2) and were compared with euthyroid women (group B). Statistical analysis was performed using SPSS Statistics version 27.0 (Armonk, NY: IBM Corp). Results A total of 7978 women delivered during the study period and the prevalence of hypothyroidism in our sample was 3.47%; 33.33% had thyroid antibodies. Women with more than one miscarriage were 30% (odds ratio {OR}: 2.06, 95% confidence interval {CI}: 1.112-3.811, p<0.05), 21.24% (OR: 1.20, 95% CI: 0.676-2.115, p>0.05), and 17% in group A1, A2, and B, respectively. The incidence of preterm births was 10% (OR: 2.22, 95% CI: 0.760-6.495, p>0.05), 4.23% (OR: 0.94, 95% CI: 0.308-2.876, p>0.05), and 4.5% in groups A1, A2, and B, respectively. Small for gestational age infants were 10% (OR: 3.33, 95% CI: 1.036-10.71, p<0.05), 5.93% (OR: 1.97, 95% CI: 0.640-6.023, p>0.05), and 3% in groups A1, A2, and B, respectively. The study revealed an association between thyroid antibodies and adverse maternal and neonatal outcomes in pregnancy. Conclusion Thyroid autoimmunity is associated with poor fetal outcomes. In Gulf countries with higher prevalence of endocrinological disorders (obesity and diabetes), thyroid disorders need attention. As fewer studies were reported from these areas with limited results in literature, this study gives an insight into the prevalence of thyroid disorders, thyroid antibodies, and their association with pregnancy outcomes.

Thyroid Autoimmunity in Pregnancy in a North-Central City in Nigeria

“…The African population has been shown to have lower thyroid autoimmunity than other racial groups (Soldin, Soldin, & Sastoque, 2007;La'ulu, & Roberts, 2007), indicating a lower prevalence in each preceding group. This is in comparison to a study done in Qatar on 7978 women, with a total of 33.33% having thyroid antibodies, a 15-fold increase (Athar et al, 2022). The risk of thyroid autoimmunity in this study was seen in more hypothyroid participants, who could present with postpartum thyroiditis weeks after a normalised TSH.…”

Frequency and structure of thyroid disfunction is at gynaecological diseases

“…3 • 2023 ISSN 2788-6190 ГІНЕКОЛОГІЯ П роблема взаємозв'язку порушень репродуктивної функції і патології щитоподібної залози (ЩЗ) активно обговорюється в науковій літературі. З одного боку, це обумовлено високою поширеністю безпліддя у шлюбі (до 15-17%), яка, не дивлячись на сучасні досягнення в галузі репродукції людини, не має тенденції до зниження [1][2][3][4]. З іншого боку, захворювання ЩЗ посідають перше місце у структурі ендокринної патології у жінок репродуктивного віку [5][6][7][8].…”